Sun Pharmaceutical Industries Ltd.
Mumbai, India
Program data pending ClinicalTrials.gov matching
70.6
Signal Score
✓ FDA Inspections (5)
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Sun Pharmaceutical Industries Ltd.
- Signal Score
- 70.6/100
- Quality Compliance
- 82.7/100 — OAI classification at Halol (2025-06-13) — CRITICAL
- Headquarters
- Mumbai, India
- Modalities
- Small Molecule API, Oral Solid Dose, Sterile Injectables, Specialty Generics, Novel Chemical Entities (NCE) via CRAMS, Biologics (via CMO partnerships), Specialty/Innovative Medicines
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Sun Pharmaceutical Industries Ltd.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
82.7
OAI classification at Halol (2025-06-13) — CRITICAL
Source: FDA Data Dashboard
OAI classification at Halol (2025-06-13) — CRITICAL
FDA Inspections5 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-02-06)
OAI classification at Halol (2025-06-13) — CRITICAL
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Oral Solid Dose, Sterile Injectables, Specialty Generics, Novel Chemical Entities (NCE) via CRAMS, Biologics (via CMO partnerships), Specialty/Innovative Medicines
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Sun Pharmaceutical Industries Ltd. FDA Inspection History
2026-02
2025-06
2025-06
2025-04
2024-12
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2026-02-06 | Vadodara | Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2025-06-13 | Halol | Drug Quality Assurance | Yes | Official Action Indicated (OAI) |
| 2025-06-13 | Panoli | Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2025-04-18 | Billerica, Massachusetts | Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2024-12-12 | Princeton, New Jersey | Bioresearch Monitoring | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Jun 29, 2026
Recent News 10 articles
Top 5 Huntingtons Disease Treatment Provider Companies - Fortune Business Insights
Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India? - Citeline News & Insights
Active Pharmaceutical Ingredients (API) Market Size, Share, 2034 - Straits Research
Sun Pharma picks up stake in US-based Krystal Biotech - VCCircle
Active Pharmaceutical Ingredients Market Report 2025-2030, By Type, Synthesis, and Geo - MarketsandMarkets
Active Pharmaceutical Ingredients (API) CDMO Market Size USD 247.60 Bn by 2035 Rising Demand for HPAPIs and Biologics Drives Growth - BioSpace
World Ethyl Acetoacetate - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature' - The Economic Times
Retinitis Pigmentosa Market Size, Share | CAGR Of 7.1% - Market.us
From Exponential Growth to PHARMA BOOM - BioSpectrum India
Frequently Asked Questions About Sun Pharmaceutical Industries Ltd.
How many FDA inspections does Sun Pharmaceutical Industries Ltd. have on record?
CDMO Signal tracks 5 FDA inspections for Sun Pharmaceutical Industries Ltd., sourced from the FDA inspection database. See the full inspection history above.
Has Sun Pharmaceutical Industries Ltd. received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Sun Pharmaceutical Industries Ltd..
What is Sun Pharmaceutical Industries Ltd.'s CDMO Signal Score?
Sun Pharmaceutical Industries Ltd. has a Signal Score of 71/100, based on quality, operations, financial stability, and capacity data.
Evaluating Sun Pharmaceutical Industries Ltd. for a manufacturing program?
Use the free AI matchmaker to compare Sun Pharmaceutical Industries Ltd. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Bend Bioscience
Bend, OR
Spray Dried Dispersion (SDD), Amorphous Solid Dispersion (ASD), Particle Engineering, Oral Solid Dose, Multiparticulates, Modified Release, Small Molecule API
Olon Group
Rodano (Milan), Italy
Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products
Codis
St. Louis, MO (US HQ); Haverhill, UK (EU operations)
Spray Dried Dispersion (SDD), Amorphous Solid Dispersion (ASD), Particle Engineering, Oral Solid Dose, Finished Dose Manufacturing, Commercial-Scale Spray Drying